• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.

作者信息

Hofman Michael S, Violet John, Hicks Rodney J, Sandhu Shahneen

机构信息

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

出版信息

Lancet Oncol. 2018 Aug;19(8):e373. doi: 10.1016/S1470-2045(18)30534-5.

DOI:10.1016/S1470-2045(18)30534-5
PMID:30102223
Abstract
摘要

相似文献

1
[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者——作者回复
Lancet Oncol. 2018 Aug;19(8):e373. doi: 10.1016/S1470-2045(18)30534-5.
2
[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者。
Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8.
3
[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.[镥]-PSMA-617放射性核素疗法治疗转移性去势抵抗性前列腺癌患者
Lancet Oncol. 2018 Aug;19(8):e372. doi: 10.1016/S1470-2045(18)30488-1.
4
Re: [Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.回复：[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者（镥PSMA试验）：一项单中心、单臂、2期研究。
Eur Urol. 2019 Mar;75(3):536-537. doi: 10.1016/j.eururo.2018.11.005. Epub 2018 Nov 15.
5
[Lu]PSMA-617 radionuclide therapy shows promise.[卢]PSMA - 617放射性核素疗法显示出前景。
Nat Rev Urol. 2018 Aug;15(8):468. doi: 10.1038/s41585-018-0029-6.
6
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
7
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.使用¹⁷⁷Lu标记的PSMA-617对转移性去势抵抗性前列腺癌进行PSMA靶向放射性核素治疗。
J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.
8
[Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?用于靶向治疗前列腺癌的[镥]-PSMA-617：神奇子弹？
Lancet Oncol. 2018 Jun;19(6):725-726. doi: 10.1016/S1470-2045(18)30268-7. Epub 2018 May 8.
9
Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.转移性去势抵抗性前列腺癌患者接受系统 PSMA 靶向治疗时，肝脏转移灶的附加局部治疗。
J Nucl Med. 2020 May;61(5):723-728. doi: 10.2967/jnumed.119.233429. Epub 2019 Oct 10.
10
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.[44Sc]Sc-PSMA-617 示踪剂在转移性去势抵抗性前列腺癌患者中的生物分布和剂量学研究。
Clin Nucl Med. 2018 May;43(5):323-330. doi: 10.1097/RLU.0000000000002003.

引用本文的文献

1
Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.转移性前列腺癌二十年的疾病演变及生物标志物指导下的临床决策制定
Int J Mol Sci. 2025 Aug 6;26(15):7593. doi: 10.3390/ijms26157593.
2
The use of radiopharmaceuticals in targeted cancer therapy: a narrative review.放射性药物在靶向癌症治疗中的应用：一项叙述性综述。
Int J Physiol Pathophysiol Pharmacol. 2025 Apr 25;17(2):37-44. doi: 10.62347/LQYR3145. eCollection 2025.
3
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future.
基于前列腺特异性膜抗原（PSMA）的疗法及晚期前列腺癌的新型疗法：现状与未来
Curr Treat Options Oncol. 2025 May;26(5):375-384. doi: 10.1007/s11864-025-01317-5. Epub 2025 Apr 23.
4
Current clinical application of lutetium‑177 in solid tumors (Review).镥-177在实体瘤中的当前临床应用（综述）
Exp Ther Med. 2024 Mar 26;27(5):225. doi: 10.3892/etm.2024.12514. eCollection 2024 May.
5
Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.放射性药物治疗学——核医学与分子影像中的精准医学。
Nanotheranostics. 2022 Jan 1;6(1):103-117. doi: 10.7150/ntno.64141. eCollection 2022.
6
Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target.实体瘤的放射免疫疗法：聚焦于Glypican-1作为放射免疫疗法靶点
Ther Adv Med Oncol. 2021 Oct 8;13:17588359211022918. doi: 10.1177/17588359211022918. eCollection 2021.
7
Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症：临床进展与挑战。
Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
8
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.精准肿瘤学的进展：靶向钍-227 缀合物作为靶向 α 治疗的新方法。
Cancer Biother Radiopharm. 2020 Sep;35(7):497-510. doi: 10.1089/cbr.2020.3568. Epub 2020 Apr 7.
9
Advances in targeted alpha therapy for prostate cancer.
Ann Oncol. 2019 Nov 1;30(11):1728-1739. doi: 10.1093/annonc/mdz270.